FDA DEVICE FACTS
Talos®-C Cervical Intervertebral Body Fusion System, Talos®-C (HA) Cervical Intervertebral Body Fusion System
Meditech Spine, LLC
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
Talos®‐C Cervical Intervertebral Body Fusion Devices The Talos®‐C Cervical Intervertebral Body Fusion Devices are indicated for intervertebral body fusion of the spine in skeletally mature patients. The Talos®‐C Cervical Intervertebral Body Fusion Devices are intended for use for anterior cervical interbody fusion in patients with cervical disc degeneration and/or cervical spinal instability, as confirmed by imaging studies (radiographs, CT, MRI), that results in radiculopathy, myelopathy, and/or pain at multiple contiguous levels from C2 ‐ T1. The Talos®‐C Cervical Intervertebral Body Fusion Devices are intended to be used with supplemental fixation. The Talos®‐C Cervical Intervertebral Body Fusion Devices are designed for use with autogenous and/or allogeneic bone graft comprised of cancellous, cortical, and/or corticocancellous bone graft to facilitate fusion. Non‐operative treatment prior to treatment with Talos®‐C Cervical Intervertebral Body Fusion Devices is six (6) weeks. Talos®‐C Cervical IBF Devices are to be implemented via an open anterior approach. Talos ®‐C Cervical IBF Devices are also to be used with supplemental fixation. Additionally, the use of Hyperlordotic devices (lordotic angle greater than 7°) are intended to be used exclusively with anterior supplemental fixation. Talos ®‐C (HA) Cervical Intervertebral Body Fusion Devices The Talos®‐C (HA) Cervical Intervertebral Body Fusion Devices are indicated for intervertebral body fusion of the spine in skeletally mature patients. The Talos®‐C (HA) Cervical Intervertebral Body Fusion Devices are intended for use for anterior cervical interbody fusion in patients with cervical disc degeneration and/or cervical spinal instability, as confirmed by imaging studies (radiographs, CT, MRI), that results in radiculopathy, myelopathy, and/or pain at multiple contiguous levels from C2 ‐ T1. The Talos®‐C (HA) Cervical Intervertebral Body Fusion Devices are intended to be used with supplemental fixation. The Talos‐C® (HA) Cervical Intervertebral Body Fusion Devices are designed for use with autogenous and/or allogeneic bone graft comprised of cancellous, cortical, and/or corticocancellous bone graft to facilitate fusion. Non‐operative treatment prior to treatment with Talos®‐C (HA) Cervical Intervertebral Body Fusion Devices is six (6) weeks. Talos®‐C(HA) Cervical IBF Devices are to be implemented via an open anterior approach. Talo s®‐C (HA) Cervical IBF Devices are also to be used with supplemental fixation. Additionally, the use of Hyperlordotic devices (lordotic angle greater than 7°) are intended to be used exclusively with anterior supplemental fixation.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。